The upgrading and transformation of active pharmaceutical ingredients is an inevitable result of competition in the pharmaceutical industry

Introduction by Zyzhan: Looking at the global market, the pharmaceutical industry is fiercely competitive. In recent years, the competition in the raw material medicine industry has gradually intensified. However, it cannot be denied that there are still many shortcomings in the entire industry.
The industry faces the most direct problems of small scale and poor product structure. There are few high value-added varieties in the formulation products, and the main export products are raw materials. For the treatment of common and frequently occurring diseases, there are relatively few large and commonly used varieties included in the national essential drug catalog, and some enterprises have single products with weak risk resistance. The phenomenon of homogenization in the production of general drugs is also quite serious. The internationalization of preparations and the export of traditional Chinese medicine need to be breakthrough, while the development of biological products and biopharmaceuticals needs to be improved.
In addition, the insufficient independent innovation capability of enterprises is also a major problem. The majority of new product development involves imitation, while there are few products with independent intellectual property rights. In addition, the bottleneck of drug production approval is prominent, and the registration and approval of idle old drugs by enterprises are difficult to flow and transfer normally.
The current trend of transformation and upgrading in the global pharmaceutical industry is becoming increasingly evident, and the prospects of the active pharmaceutical ingredient industry are very broad. How to leverage the advantages of active pharmaceutical ingredients has become a hot topic of concern for the industry.
If the raw material pharmaceutical industry wants to truly consolidate its dominant position, it needs to accelerate the pace of transformation and upgrading, shift to the production of formulations and specialty raw materials on the basis of ensuring the quality of raw materials, change its development concept, and shift from price advantages to technological advantages.
The emerging biomedical industry is in the ascendant, the modernization process of traditional Chinese patent medicines and simple preparations is accelerating, medical engineering industries such as new medical materials and medical devices are growing, and the accelerated development of the industry is in progress. API companies, especially large enterprises with certain technological strength, should actively shift towards the production of formulations and specialty APIs.
(Source: China Pharmaceutical Machinery Equipment Network)